Connect with us

National

ACE2 agonist C21 relieves respiratory difficulty in COVID-19 – News-Medical.Net

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host…

Published

on

post featured image

The advent of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to over 2.2 million deaths over a period of just over a year. The lack of effective drugs to combat the virus has led to intensive research to identify preventive and therapeutic antivirals.
A new preprint on the medRxiv* server describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting…

Click here to view the original article.